Additional layers of complexity and uncertainty continue to be added to how life sciences companies bring their products to market as more stakeholders become involved in the commercialization process. While much emphasis is placed on company compliance with regulatory requirements – less emphasis has been placed on vendors or global commercial partners. By not having an established auditing, monitoring and surveillance program of third parties, an undue amount of risk and uncertainty can be imposed on drug manufacturers and their products.
Listen to our educational, on-demand presentation about drug safety governance when working with third parties. Our colleagues discuss:
For more information on this topic, or to learn how Baker Tilly’s Value Architects™ can help, contact our team.